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SUMMARY – Overweight and physical inactivity adversely affect endothelial function and are 
risk factors for atherosclerosis and cardiovascular disease. Both Crataegus extract WS 1442 and physi-
cal exercise exert beneficial effects on endothelial function. We investigated whether WS 1442 and 
Nordic walking (NW) had comparable effects on endothelial function and lipid profile in overweight 
subjects. In this partially blinded pilot study, overweight, otherwise healthy volunteers aged 45-75 
years were randomized into four groups as follows: WS 1442 2x450 mg/day (WS-standard), WS 1442 
2x900 mg/day (WS-double), exercise 2x30 minutes/week (NW-low), and exercise 4x45 minutes/week 
(NW-high) for 12 weeks. Safety was assessed based on adverse events. Endothelial function testing 
(EndoPAT®), assessment of endothelial progenitor cells, lipid profiles, and treadmill testing were per-
formed. Sixty subjects participated in the study. At baseline, subjects in WS-standard/-double groups 
had higher lipid levels and greater impairment of endothelial function. Subjects with impaired endo-
thelial function showed improvement regardless of the type of intervention. Subjects in WS-standard 
and WS-double groups showed a trend towards modest decrease in triglycerides and modest increase 
in HDL-cholesterol; most changes were within the normal limits. In NW-low/-high groups, values 
also remained within the normal range. Exercise capacity improved in both NW groups. WS-double 
showed no additional benefits over WS-standard. All adverse events were unrelated or improbably 
related to treatment. In conclusion, WS 1442 and exercise training were safe and showed beneficial 
effects on endothelial function and lipid profile in overweight but otherwise healthy volunteers; exer-
cise capacity improved only by Nordic walking.
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Introduction
Overweight is among the leading modifiable risk 
factors for the development of cardiovascular disease 
(CVD)1. Current guidelines recommend weight loss 
through dietary measures and increased physical activ-
ity. While these provisions may suffice in an otherwise 
healthy population2, subjects with relevant comorbidi-
ties such as arterial hypertension, diabetes mellitus, or 
diseases aggravated by overweight may require addi-
tional pharmacological treatment.
WS 1442, the active ingredient of the herbal me-
dicinal product Crataegutt® (Dr. Willmar Schwabe 
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GmbH & Co. KG, Karlsruhe, Germany), is a dry ex-
tract from Crataegus leaves with flowers (4-6.6:1), ex-
traction solvent: ethanol 45% (w/w). The extract is ad-
justed to 17.3%-20.1% oligomeric procyanidins and 
contains flavonoids3. WS 1442 has been registered in 
several European countries as a phytopharmaceutical 
medicinal product for the treatment of heart failure 
(HF) (stage II in the New York Heart Association 
classification), with a recommended daily dose of up to 
900 mg.
Endothelial dysfunction (ED) is an early marker 
for the development of CVD that can be detected be-
fore the onset of structural changes to the vessel wall4. 
WS  1442 causes vasorelaxation by an endothelium-
dependent and nitric oxide-mediated mechanism5,6, by 
supporting endothelium-derived hyperpolarizing fac-
tor-mediated vasorelaxation, and by reducing endo-
thelium-dependent contractile responses7, and reduces 
stiffness of the endothelial surface layer8. It is assumed 
that an increased coronary blood flow, reduced ED, in-
hibition of lipid oxidation and anti-inflammatory 
properties contribute to its cardioprotective effects9. 
Owing to these pharmacological properties6,8 and in 
combination with its favorable safety profile10-12, 
WS 1442 may have beneficial effect on ED and lipid 
parameters in overweight but otherwise healthy indi-
viduals who are at an increased cardiovascular risk 
(CVR) related to atherosclerosis.
As marketing authorizations for Crataegus extract 
preparations (including WS 1442) as medicinal prod-
ucts have been granted based on monographs and sci-
entific literature13,14, no data on healthy volunteers 
have been available to date.
Physical exercise has been shown to exert beneficial 
effects on elevated serum lipids, diabetes mellitus and 
arterial hypertension. Furthermore, morphological 
and functional parameters such as endothelial (dys)
function may be improved. In a healthy population, 
increased CVR resulting from overweight may be 
ameliorated through dietary measures in combination 
with physical exercise, even when the individual’s 
weight is actually not reduced15-17. Physical exercise is 
therefore an ideal ‘control group’ to compare the effects 
of WS 1442 with an intervention already shown to ex-
hibit beneficial effects on ED and lipid metabolism.
We therefore tested two hypotheses; thus, the pri-
mary hypothesis of this randomized pilot study was to 
obtain first information on the safety of two different 
doses of WS 1442 in overweight but otherwise healthy 
volunteers. Secondly, we aimed at exploring the effects 
of WS 1442 on the measures of endothelial function in 
comparison to physical exercise the benefits of which 




This was a single-center, randomized, phase I pilot 
study with four parallel groups comparing two dosages 
of WS  1442 and two intensities of physical exercise 
over a period of 12 weeks. Treatments were double-
blind concerning comparison between WS  1442 
900  mg/day and 1,800  mg/day, and open-label for 
comparison between WS 1442 and physical exercise. 
Due to the exploratory concept of the trial, no pre-
specified hypotheses were tested.
Ethics
The study was performed under consideration of 
the principles of the Good Clinical Practice and Dec-
laration of Helsinki and registered in clinicaltrials.gov 
(NCT00982501). The independent ethics committee 
of the federal State of Salzburg, Austria, reviewed 
and approved the trial protocol (registration no. 
415-E912/14-2008). Informed consent was obtained 
from all subjects.
Subjects
Participants were overweight (body mass index, 
BMI: 25.0-29.9 kg/m2) but otherwise healthy volun-
teers without regular physical exercise training during 
the last three months before enrolment. Male and fe-
male subjects aged 45-75  years, with blood pressure 
≤140/90  mm  Hg, normal resting electrocardiogram 
(ECG) and normal ECG stress test were eligible for 
inclusion. The main exclusion criteria were regular in-
take of any medication (except for oral contraceptives), 
echocardiographic evidence of any cardiac disease, 
FEV1/FVC ratio <70%, clinically important physical 
or psychiatric diseases, abnormal urinalysis including 
microalbuminuria, and nicotine consumption. Con-
comitant intake of other hawthorn preparations or di-
etary supplements with a potential influence on the 
study outcome measures was prohibited.
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The study was performed at the Institute of Sports 
Medicine, Prevention and Rehabilitation of the Para-
celsus Medical University in Salzburg, Austria. Adver-
tisements in local newspapers were used for subject 
recruitment.
Interventions
WS 1442 was available in film-coated tablets con-
taining 450  mg extract. Treatment group  1 received 
one WS  1442 tablet and one placebo tablet b.i.d. 
(WS-standard; total daily dose: 900 mg), and group 2 
received two WS 1442 tablets b.i.d. (WS-double; total 
daily dose: 1,800 mg). The tablets were to be taken un-
chewed in the morning and in the evening with some 
water. Placebo and WS 1442 tablets were identical in 
size and appearance.
The subjects in the exercise training did not receive 
any investigational drugs (including placebo) but prac-
ticed Nordic walking (NW) for 2x30 minutes (group 3, 
light exercise; NW-low) or for 4x45 minutes per week 
(group 4, moderate exercise; NW-high). Eligible sub-
jects were randomized to study groups using an alloca-
tion ratio of 1:1:1:1 without further stratification. The 
random code was generated by a member of the man-
ufacturer’s Biometrics Department otherwise not in-
volved in the study, using a validated random number 
generator (RCODE). Upon randomization, each sub-
ject received the lowest available random number. An 
authorized investigator enrolled the participants. The 
number was attached to a sealed envelope that includ-
ed a document showing either the type of exercise or 
medication number, and concealed the intervention 
until assignment. After random code assignment, dis-
tinction between drug treatment and NW, and be-
tween the NW-low and NW-high conditions was 
open for study participants and investigational staff, 
whereas distinction between WS-low and WS-high 
remained double-blind.
The subjects in the exercise training groups had to 
participate in regular NW workouts guided by instruc-
tors. We used NW as exercise intervention due to the 
well-documented applicability in untrained partici-
pants18. Subjects received walking poles and a heart 
rate monitor and were introduced into their use. Exer-
cise training was performed at >70% of the maximum 
heart rate achieved during treadmill test, representing 
the heart rate corresponding to approximately 3-4 
mmol/L of blood lactate.
Study schedule
Screening and baseline examinations were per-
formed to assure the subject eligibility for the trial in-
cluding medical history assessments, anthropometric 
measurements, physical status, resting ECG, echocar-
diography, exercise stress testing19, spirometry, and 
safety laboratory tests including urinalysis. After ran-
domization during the baseline visit, eligible subjects 
underwent 12-week intervention, with follow-up vis-
its at the end of weeks 6 and 12. Vital signs were as-
sessed at all visits, and laboratory tests were repeated at 
the final visit. At baseline and during the final visit, 
treadmill ergometry with lactate testing was performed 
and endothelial function was assessed. During all vis-
its, adverse events (AEs) were recorded.
Outcomes
Endothelial function was assessed noninvasively by 
determining the Reactive Hyperemia Index (RHI) us-
ing an Endo-Pat2000 device (Itamar Medical Ltd., 
Israel). The test is based on endothelium-mediated re-
laxation of arteries at the distal phalanx of a finger as a 
reaction to five-minute occlusion of the brachial artery, 
using a standard blood pressure cuff. RHI is defined as 
the ratio between the peripheral arterial tone before 
and after the occlusion. The score is significantly cor-
related with CVR factors20,21 and has been validated as 
a predictor of cardiovascular outcomes22. It has been 
shown to be sensitive to change induced by treat-
ment23. A cut-off value of 1.67 provides 82% sensitiv-
ity and 77% specificity for diagnosing coronary ED21. 
The device also computes the Augmentation Index 
(AI), a measure of arterial stiffness related to age and 
atherosclerosis24.
Treadmill testing was used to determine the 
2 mmol/L and 4 mmol/L lactate thresholds (aerobic 
threshold and anaerobic threshold) according to the 
method described by Heck et al.25 and maximum indi-
vidual performance (heart rate). Participants were in-
structed to exercise until subjective exhaustion or a 
systolic blood pressure ≥250  mm  Hg was reached19. 
Treadmill exercise commenced at a speed of 2 km/h 
and slope of 1.5% and was increased to 4 and 6 km/h 
during the second and third step, respectively. In the 
fourth step, the slope was increased to 5%, with addi-
tional increases by 5% during each subsequent step. 
The duration of each step was 3 minutes. Lactate con-
D. Niederseer et al. Safety and effects of WS 1442 on lipid profile and endothelial function
Acta Clin Croat, Vol. 58, No. 4, 2019 607
centrations were determined by blood sampling from 
the earlobe before the start of treadmill exercise and at 
the end of each step. Further samples were taken at 1, 
3 and 5 minutes after exercise cessation.
Additionally, quantitative measurement of endo-
thelial progenitor cells (EPCs) related to the progres-
sion of CVD due to their role in plaque formation, 
vasculogenesis, angiogenesis and other pathways26 was 
conducted. Decreased numbers of EPCs were shown 
to correlate with CVR factors, disease progression and 
prognosis of coronary artery disease27. Peripheral blood 
mononuclear cells were separated via density gradient 
centrifugation and incubated with specific antibodies 
(10 µL per 107 cells) as follows: CD3 (fluorescein iso-
thiocyanate; BD Pharmingen), CD34 (phycoerythin; 
BD Pharmingen), CD45 (peridinin chlorophyll pro-
tein; BD Pharmingen) and KDR/anti-VEGFR2 (al-
lophycocyanin, mouse IgG1, R & D Systems). Acqui-
sition was performed on a FACSCalibur® cytometer 
(Becton Dickinson, Belgium). Analysis and gating was 
performed using FlowJo 9.0.1 (Tree Star, Inc., Ash-
land, OR, USA) software for Macintosh. Lymphocyte 
population was plotted in a CD45/sideward scatter 
plot, and CD45+ cells were selected for further analy-
sis. To rule out common lymphocyte populations and 
to increase the sensitivity for EPCs, CD3 positive cells 
were excluded using a CD45/CD3 plot. The numbers 
and percentages of triple positive cells for CD45+, 
CD34+ and KDR+ were determined. Altogether, cells 
positive for CD45+/CD34+/KDR+ and negative for 
CD3- were defined to be EPCs. To homogenize the 
sample size, the first 106 events were recorded and ana-
lyzed. For better visualization of cells with low num-
bers, logarithmic transformation (log  10) was per-
formed to determine absolute EPC level values28.
Lipid profiles of the study subjects were assessed 
using fasting venous blood samples. Triglycerides, 
HDL-cholesterol, and total cholesterol were analyzed 
using Roche/Hitachi Systems (Roche Diagnostics 
GmbH, Mannheim, Germany); LDL-cholesterol was 
analyzed using Cobas Integra 400/700/800 for direct 
measurement of LDL-cholesterol.
Statistics
In accordance with the concept of the trial as an 
exploratory pilot study, descriptive statistical analyses 
were performed and no formal hypotheses were tested. 
For outcomes related to ED, missing data at treatment 
end were replaced by the values obtained at week 6 if 
available. All analyses were based on all subjects who 
were randomized and treated.
A total sample size of 60 subjects was planned to 
obtain at least 4x12 subjects for ED evaluation. The 
sample size was chosen to obtain an acceptable preci-
sion on summary statistics for the outcomes of inter-
est29 for further study planning.
Results
Study participants
A detailed and structured telephone interview was 
carried out with 417 subjects responding to the adver-
tisements. Based on the inclusion and exclusion criteria, 
we screened 79 subjects and 60 subjects were then ran-
domized (15 per group), whereas 19 did not meet the 
inclusion criteria or met an exclusion criterion. One 
subject in the WS-standard group revoked informed 
consent before the first administration of the investiga-
tional treatment and was therefore excluded from all 
analyses. One subject in each group was withdrawn pre-
maturely during randomized treatment due to an AE; 
however, all events leading to premature termination 
were unrelated to the investigational treatments.
All treated subjects were analyzed for safety and 
pharmacodynamic measures (ED), lipid profile and 
exercise capacity (Fig. 1).
Table 1 presents baseline characteristics of study 
subjects. Individual baseline lipid values were either 
within the applicable reference ranges or considered to 
be clinically irrelevant. The mean drug compliance was 
98.7% and 97.8% of tablets taken relative to the pre-
scribed amount for WS-standard and WS-double, re-
spectively. The mean exercise attendance in both NW 
groups was 93%.
Pharmacodynamic effects
Regarding endothelial function, subjects random-
ized to WS 1442 exhibited lower (i.e. less favorable) 
baseline mean RHI values, and a higher percentage of 
these subjects were at an increased CVR (RHI <1.67), 
as compared with NW-groups. However, the mean 
baseline augmentation indices were comparable and 
all treatment groups showed elevated baseline aug-
mentation index mean values.
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During the study period, subjects in the WS-stan-
dard group showed numerical improvements of RHI 
and AI, whereas all other groups showed deteriora-
tions of the respective parameters (Table 1). However, 
in all groups, subjects with baseline RHI <1.67 exhib-
ited mean RHI improvements by 17%-22% as com-
pared to their baseline values. The percentage of sub-
jects with any RHI improvement during randomized 
treatment was highest in WS-standard group followed 
by NW-high group. Regarding AI change, the highest 
percentage of subjects with improvement was recorded 
in the WS-double group followed by WS-standard 
group.
At baseline, the number of EPCs was lower in sub-
jects randomized to WS-standard and WS-double 
(log scale: 0.88±0.56 and 0.82±0.65) compared to 
NW-low and NW-high (0.95±0.53 and 0.91±0.49). 
Subjects receiving WS-standard showed the largest 
numerical increase of EPC counts by 0.66±0.74 log 
units; all other groups exhibited increases by less than 
0.4 SD log units.
During treadmill testing (Table 2), the subjects 
randomized to NW-high showed greatest improve-
ments of all treatment groups, with the mean increase 
in workload increments versus baseline of 0.6±0.5 steps 
and increase in exercise time of 1.1±1.4 minutes. This 
was accompanied by elevations of the aerobic/anaero-
bic thresholds regarding both workload increments 
and exercise time. The subjects randomized to NW-
low showed similar but less pronounced effects. In the 
subjects treated with WS 1442, exercise tolerance re-
mained essentially unchanged.
Fig. 1. Distribution of study subjects according to intervention groups.
The numbers of subjects with relevant protocol deviations were 6/14, 3/15, 5/15 and 3/15 for WS-standard, WS-double, NW-
low and NW-high, respectively. Relevant violations were premature withdrawal during the first 10 weeks of randomized treat-
ment (1/1/1/1 subjects), an inappropriate FEV1/FVC ratio at inclusion (0/1/0/0), non-adherence to the treatment or visit 
schedule (0/0/1/1), missing pharmacodynamic examinations (2/0/1/1), and use of prohibited concomitant medication 
(4/1/2/0).
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Safety and tolerability
The percentages of subjects with any AE during 
the study period were similar in all treatment groups 
except for NW-low, where fewer participants reported 
such events (Table 3). Most AEs were symptoms of 
the musculoskeletal system (e.g., arthralgia, back pain) 
or trivial infections. Four subjects exposed to WS 1442 
had a total of seven events (arthralgia, chest discom-
fort, diarrhea, forehead headache, abdominal fullness, 
charley horse and tinnitus), in which a causal relation-
ship with the investigational treatment was considered 
unlikely; in all other cases, causal relationship was ex-
cluded. Four of the seven events with unlikely causal 
relationship were observed in one patient. One serious 
AE was observed in the WS-double group (premature 
termination of the study to undergo a pre-planned 
umbilical hernia repair); therefore, causal relationship 
with the investigational treatment could be excluded. 
Individual vital signs and safety laboratory measures in 
all treatment groups were uneventful except for abnor-
mal values that were attributable to concomitant dis-
eases reported as AEs.
During randomized treatment, serum triglycerides 
decreased within the normal range in subjects receiv-
ing WS 1442 but not in NW groups (Table 1). In ad-
dition, subjects randomized to WS  1442 showed an 
increase in HDL-cholesterol that was not seen in the 
light exercise condition. There was a slight decrease 
Table 2. Treadmill ergometry test: baseline values and increase from baseline to the end of randomized treatment 
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Number of subjects with any adverse events (%) 11 (78.6%) 12 (80.0%) 11 (73.3%) 8 (53.3%)
Total number of adverse events 16 24 14 17
Causal relationship of adverse events  
to study medication: 
No. of events with no relationship 14 19 Not applicable Not applicable
No. of events with causal relationship unlikely 2 5 Not applicable Not applicable
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within the normal range in LDL-cholesterol in all 
groups.
Discussion
This was the first systematic investigation of safety 
and effects of the Crataegus extract WS 1442 in over-
weight, otherwise healthy volunteers. Results regard-
ing tolerability and safety of the extract were not in-
dicative of any previously unknown risks associated 
with the product. They therefore support the favorable 
safety profile of WS 1442 as previously observed in pa-
tients with HF10-12. This applies to the recommended 
and marketed dose of 900  mg/day, as well as to the 
double dose of 1,800 mg/day. The study did not show 
any signal that subjects in WS-double group might be 
at an appreciably higher risk of AEs than those in 
WS-standard group. However, the validity of this in-
terpretation is limited by the small sample size of this 
exploratory pilot study.
The baseline lipid profiles of most study subjects 
were within the normal limits, and any elevated values 
were considered to be clinically irrelevant. Participants 
randomized to WS-standard showed further decreases 
of triglycerides, which were accompanied by increases 
in HDL-cholesterol. These observations are consistent 
with the findings in animal models30 and patients with 
chronic, stable HF of NYHA class III31,32. They there-
fore justify further investigations of the lipid lowering 
effects of WS 1442. No changes in lipid profiles were 
observed in NW groups.
All subjects with baseline ED showed an average 
RHI increase during intervention, whereas the mean 
RHI remained essentially unchanged throughout the 
study period in those with normal baseline endothelial 
function. As more subjects with impaired endothelial 
function were randomized to WS  1442, the mean 
RHI increased in these groups to near normal values, 
whereas RHI in the NW groups was normal already at 
baseline and remained so throughout the study. The 
mean EPC counts increased in all study groups 
throughout the intervention period, with the most 
pronounced changes observed in the WS-standard 
group. These results indicated that subjects who were 
at an increased CVR due to overweight and inactivity, 
notably those in whom limitations of endothelial func-
tion were already measurable, might benefit from 
treatment with WS 1442 through improvement of im-
portant functional markers, including RHI normaliza-
tion. However, the study did not support an additional 
benefit of WS 1442 1,800 mg/day over the 900 mg/
day dosage in the investigated sample, meaning that 
we did not find a dose dependent effect of WS 1442. 
Yet, this finding has to be interpreted with caution be-
cause our study was underpowered to answer such a 
research question. Further adequately powered studies 
could clarify this interesting issue.
Physical exercise training has been shown to im-
prove ED15,16,33-35. NW was therefore chosen in this 
study as an active control with proven, well-document-
ed efficacy in the population of interest, in order to 
obtain an ‘anchor’ for the effects to be expected from 
WS 1442 in the same indication. Although it is quite 
unfortunate that this comparison was affected by coin-
cidental baseline imbalance, our results nevertheless 
indicated that WS 1442 might induce effects on ED 
and EPCs similar to those of exercise training17,36. This 
interpretation is, however, only hypothesis-generating 
and requires confirmation in a larger study.
Unlike WS 1442, NW had beneficial effects on ex-
ercise capacity, the most predictive single parameter 
for cardiovascular events37. Therefore, the increase in 
exercise capacity might be clinically most significant of 
the changes observed, with the highest impact on 
CVR. A major problem with the promotion of exer-
cise training is poor long-term compliance38. In our 
study, two of the 30 subjects in the NW groups with-
drew from the intervention while all other subjects in 
these groups (93%) completed all training sessions and 
exercised with appropriate heart rates. Compliance 
was therefore much higher than in the HF-ACTION 
trial39, where 84% of the patients were compliant dur-
ing the initial 36 supervised sessions while a decrease 
to 62% at one year and to 40% at three years was docu-
mented during subsequent individual home-based 
training. Poor compliance thus remains a major chal-
lenge in the promotion of exercise training.
Except for one subject who revoked the informed 
consent before the first administration, no other sub-
ject in the WS 1442 groups exhibited major treatment 
compliance problems. Nevertheless, compliance has 
also been identified as a relevant issue in preventive 
pharmacotherapy, as demonstrated in the EU-
ROASPIRE trials40. Current guidelines and recom-
mendations suggest physical exercise training and di-
etary measures in otherwise healthy individuals who 
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are overweight but not obese, whereas pharmacologi-
cal treatment is only recommended if comorbidities 
are already present2,41. Individuals at risk of CVD may 
nevertheless prefer a drug over lifestyle modification, 
or they may not be able to exercise due to physical dis-
ability. In such cases, WS 1442 may be a viable option 
if a prophylactic and therapeutic effect on endothelial 
function can be confirmed in this population.
The main limitation of our study was the small 
sample size. It is the nature of a pilot study that it is 
only hypothesis-generating and does not provide defi-
nite answer to the research question proposed.
The results of this pilot study indicated that Cra-
taegus extract WS 1442 might have a beneficial effect 
on the lipid profile and endothelial function, similar to 
the effects of regular exercise training, and without sig-
nals of unwanted effects. Nonetheless, beneficial 
changes in exercise capacity could only be achieved 
through exercise training. Although the results of this 
small-sample pilot study should be interpreted cau-
tiously and the comparison between WS  1442 and 
NW may have been biased by coincidental baseline 
imbalance, it may nevertheless be worthwhile to fur-
ther investigate the potential of the extract as a preven-
tive tool in the armamentarium against the develop-
ment of CVD in overweight, inactive, yet otherwise 
healthy individuals.
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Sažetak
NEŠKODLJIVOST I DJELOTVORNOST GLOGOVA EKSTRAKTA WS 1442  
I NORDIJSKOG HODANJA NA PROFIL LIPIDA I FUNKCIJU ENDOTELA: RANDOMIZIRANO,  
DJELOMICE SLIJEPO PROBNO ISTRAŽIVANJE U DOBROVOLJACA PREKOMJERNE  
TJELESNE TEŽINE
D. Niederseer, E. Ledl-Kurkowski, K. Kvita, P. Funk i J. Niebauer
Prekomjerna težina i tjelesna neaktivnost štetno djeluju na funkciju endotela i predstavljaju rizične čimbenike za atero-
sklerozu i srčanožilne bolesti. Glogov ekstrakt WS 1442 i tjelesna aktivnost oboje utječu povoljno na endotelnu funkciju. 
Ispitivali smo imaju li WS 1442 i nordijsko hodanje (NH) usporedive učinke na endotelnu funkciju i profil lipida u osoba 
prekomjerne tjelesne težine. U ovom djelomice slijepom probnom istraživanju su inače zdravi dobrovoljci prekomjerne tjele-
sne težine u dobi od 45 do 75 godina nasumce podijeljeni u četiri skupine: WS 1442 2x450 mg/dan (standardna doza WS), 
WS 1442 2x900 mg/dan (dvostruka doza WS), tjelovježba 2x30 minuta na tjedan (niska razina NH) i tjelovježba 4x45 
 minuta na tjedan (visoka razina NH) kroz 12 tjedana. Neškodljivost se procjenjivala na osnovi štetnih događaja. Provedeno 
je testiranje endotelne funkcije (EndoPAT®), procjena endotelnih progenitorskih stanica, profila lipida te test opterećenja. U 
istraživanju je sudjelovalo 60 ispitanika. Ispitanici na standardnoj/dvostrukoj dozi WS imali su bazalno više razine lipida i 
veći poremećaj endotelne funkcije. Ispitanici s poremećenom endotelnom funkcijom pokazali su poboljšanje bez obzira na 
vrstu intervencije. Ispitanici na standardnoj i dvostrukoj dozi WS pokazivali su tendenciju ka skromnom sniženju triglicerida 
i skromnom porastu HDL-kolesterola; većina ovih promjena bila je unutar normalnih granica. Uz nisku/visoku razinu NH 
vrijednosti su također ostale unutar normalnog raspona. Sposobnost za tjelovježbu poboljšala se u objema skupinama NH. 
Dvostruka razina WS nije pokazala dodatnih koristi u usporedbi sa standardnom dozom WS. Svi štetni događaji bili su 
nevezani ili malo vjerojatno povezani s tretmanom. U zaključku, WS 1442 i tjelovježba pokazali su se neškodljivima i imali 
su povoljan učinak na funkciju endotela i profil lipida kod inače zdravih osoba prekomjerne tjelesne težine; sposobnost za 
tjelovježbu poboljšala se samo pomoću NH.
Ključne riječi: Glogov ekstrakt WS 1442; Vježbanje; Prekomjerna tjelesna težina; Endotelne progenitorske stanice
